Mobile

Randomized Phase II open-label controlled study of EMD 72000 (matuzumab) in combination with the chemotherapy regimen ECX or the chemotherapy regimen ECX alone as first-line treatment in subjects with...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-000146-36

Randomized Phase II open-label controlled study of EMD 72000 (matuzumab) in combination with the chemotherapy regimen ECX or the chemotherapy regimen ECX alone as first-line treatment in subjects with metastatic esophago-gastric adenocarcinoma

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to determine the response rates of matuzumab in combination with ECX as background chemotherapy and of ECX alone in subjects with metastatic esophago-gastric cancer.

Critère d'inclusion

  • Metastatic Esophago-gastric adenocarcinoma

Liens